BenevolentAI
Ngai Yi Mok is an experienced computational chemist currently working at BenevolentAI since May 2018. Prior to this role, Ngai Yi Mok served as a Senior Scientific Officer and PDTF Computational Chemist/Molecular Modeller at the Cancer Therapeutics Unit at the Institute of Cancer Research from May 2012 to May 2018. Ngai Yi Mok began a career as a computational chemist at the Drug Discovery Unit of the University of Dundee from 2009 to 2012. Academic qualifications include a PhD in Computational & Medicinal Chemistry, a Master's degree in Chemical Biology, and a Bachelor's degree in Chemistry and Pharmacology, all obtained from the University of Leeds between 2001 and 2009.
This person is not in any teams
This person is not in any offices
BenevolentAI
8 followers
BenevolentAI combines advanced AI and machine learning with cutting edge science to decipher complex disease biology, generate novel insights and discover more effective medicines. Our unique computational R&D platform spans every step of the drug discovery process, powering an in-house pipeline of 25+ drug programmes from early discovery towards clinical phases. With several successful collaborations with leading pharmaceutical organisations, we are also the only AI-drug discovery company with a clinically validated approach, discovering a leading repurposed drug candidate for COVID-19. BenevolentAI is headquartered in London with a research facility in Cambridge (UK) and a further office in New York, with a team of over 300 world-leading scientists and technologists progressing its mission to reinvent drug discovery and advance life-changing drugs through to the clinic.